When did NovoCure report Q1 2025 earnings?

NovoCure (NVCR) reported Q1 2025 earnings on April 24, 2025 before market open.

What were NovoCure's Q1 2025 revenue and EPS?

NovoCure reported revenue of $155.0M and eps of $-0.31 for Q1 2025.

Did NovoCure beat estimates in Q1 2025?

Revenue beat the consensus estimate of $153.9M by $1.1M. EPS beat the consensus estimate of $-0.47 by $0.16.

How did NovoCure's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 11.9% from $138.5M a year earlier and eps grew 13.9% from $-0.36.

Where can I find NovoCure's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0001645113-25-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.

NovoCure NVCR Q1 2025 earnings

Reported April 24, 2025 · Before market open

Revenue$155.0MBeat by $1.1M

EPS-$0.31Beat by $0.16

Revenue estimate$153.9M

EPS estimate-$0.47

Next report

Date not yet announced

Financials

Q1 2025

Income statement

See full

Revenue$155.0M+11.9%

Gross profit$116.5M+11.1%

Operating income-$37.9M+8.8%

Net income-$34.3M+11.5%

EPS (diluted)-$0.31+13.9%

Balance sheet

See full

Cash & equivalents$127.3M-72.0%

Total debt$40.3M-93.2%

Total equity$362.0M+0.7%

Total assets$1.2B+11.4%

Cash flow

See full

Operating cash flow-$35.7M-13.0%

CapEx$10.6M-10.0%

Free cash flow-$46.3M-6.7%

Valuation & ratios

Valuation

as of 03/31/25

See full

Market cap$1.96B+16.8%

Enterprise value$1.87B+3.0%

P/S3.2×0.0×

Profitability

See full

Gross margin77.2%+2.3pp

Operating margin-26.8%-6.8pp

Net margin-26.4%-5.8pp

FCF margin-11.6%-3.8pp

Returns & leverage

See full

Return on equity-45.5%-2.8pp

Debt / equity0.1×-1.5×

Current ratio1.5×-4.8×

Segments

By geography

See full

United States$93.2M—

Germany$18.7M—

France$17.9M—

Japan$8.7M—

Greater China$4.6M—

Versus estimates

Revenue

Q2 2026$183.6MBeat by $11.1M Q1 2026$174.1MBeat by $6.3M Q4 2025$174.4MIn line Q3 2025$167.2MMiss by $7.2M Q2 2025$158.8MIn line

Q1 2025$155.0MBeat by $1.1M

Diluted EPS

Q2 2026-$0.13Beat by $0.20 Q1 2026-$0.62Miss by $0.11 Q4 2025-$0.22Beat by $0.19 Q3 2025-$0.33Beat by $0.09 Q2 2025-$0.36Beat by $0.03

Q1 2025-$0.31Beat by $0.16

Ask the moment NovoCure reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did NovoCure report Q1 2025 earnings?: NovoCure (NVCR) reported Q1 2025 earnings on April 24, 2025 before market open.
What were NovoCure's Q1 2025 revenue and EPS?: NovoCure reported revenue of $155.0M and eps of $-0.31 for Q1 2025.
Did NovoCure beat estimates in Q1 2025?: Revenue beat the consensus estimate of $153.9M by $1.1M. EPS beat the consensus estimate of $-0.47 by $0.16.
How did NovoCure's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 11.9% from $138.5M a year earlier and eps grew 13.9% from $-0.36.
Where can I find NovoCure's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0001645113-25-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.